Eckert & Ziegler (EUZ) Stock Overview
Manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for EUZ from our risk checks.
EUZ Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Eckert & Ziegler SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €15.43 |
| 52 Week High | €23.25 |
| 52 Week Low | €13.30 |
| Beta | 1.48 |
| 1 Month Change | 2.73% |
| 3 Month Change | 2.94% |
| 1 Year Change | -29.33% |
| 3 Year Change | 17.73% |
| 5 Year Change | -51.45% |
| Change since IPO | 646.61% |
Recent News & Updates
Recent updates
Analysis Article • Mar 30
Earnings Miss: Eckert & Ziegler SE Missed EPS By 29% And Analysts Are Revising Their Forecasts
Eckert & Ziegler SE ( ETR:EUZ ) last week reported its latest annual results, which makes it a good time for investors...Analysis Article • Jan 10
Why Eckert & Ziegler SE (ETR:EUZ) Could Be Worth Watching
While Eckert & Ziegler SE ( ETR:EUZ ) might not have the largest market cap around , it saw a decent share price growth...Analysis Article • Sep 29
What Eckert & Ziegler SE's (ETR:EUZ) P/E Is Not Telling You
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider...
Narrative Update • Sep 19
Expanding Radioisotope Production Will Fuel Global Personalized Medicine
The upward revision in Eckert & Ziegler’s price target reflects modest improvements in both future P/E and net profit margin, resulting in a new consensus fair value of €22.85. What's in the News Confirmed 2025 earnings guidance with expected sales of approximately €320 million and EBIT before special items of about €78 million.Analysis Article • Sep 13
Do Eckert & Ziegler's (ETR:EUZ) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narrative Update • Sep 04
Expanding Radioisotope Production Will Fuel Global Personalized Medicine
With no material changes in either the discount rate or future P/E ratio, analysts left Eckert & Ziegler’s fair value estimate effectively unchanged at €21.67. What's in the News Eckert & Ziegler confirmed 2025 guidance, expecting sales of around €320 million and EBIT before special items of around €78 million.Analysis Article • Jun 12
The Compensation For Eckert & Ziegler SE's (ETR:EUZ) CEO Looks Deserved And Here's Why
Key Insights Eckert & Ziegler to hold its Annual General Meeting on 18th of June Salary of €360.0k is part of CEO...Analysis Article • May 20
Eckert & Ziegler's (ETR:EUZ) Solid Earnings Have Been Accounted For Conservatively
Investors signalled that they were pleased with Eckert & Ziegler SE's ( ETR:EUZ ) most recent earnings report...Analysis Article • May 08
Eckert & Ziegler SE's (ETR:EUZ) P/E Is Still On The Mark Following 27% Share Price Bounce
Eckert & Ziegler SE ( ETR:EUZ ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Analysis Article • Apr 19
What Is Eckert & Ziegler SE's (ETR:EUZ) Share Price Doing?
Eckert & Ziegler SE ( ETR:EUZ ), is not the largest company out there, but it saw a decent share price growth of 16% on...Analysis Article • Mar 17
Eckert & Ziegler (ETR:EUZ) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Feb 28
If EPS Growth Is Important To You, Eckert & Ziegler (ETR:EUZ) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
New Narrative • Feb 10
European GalliaPharm Approval And Telix Partnership Will Open New Markets And Strengthen Future Prospects
European market expansion via GalliaPharm approval and strategic partnerships drive new revenue streams and improved earnings potential.Analysis Article • Aug 08
Eckert & Ziegler SE's (ETR:EUZ) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 25x Eckert & Ziegler SE ( ETR:EUZ ) may be sending bearish signals at the...Analysis Article • Jul 17
Does Eckert & Ziegler (ETR:EUZ) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jun 20
Why We Think Eckert & Ziegler SE's (ETR:EUZ) CEO Compensation Is Not Excessive At All
Key Insights Eckert & Ziegler's Annual General Meeting to take place on 26th of June Total pay for CEO Harald...Analysis Article • Jun 05
Investors Met With Slowing Returns on Capital At Eckert & Ziegler (ETR:EUZ)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Analysis Article • May 13
Is Now An Opportune Moment To Examine Eckert & Ziegler SE (ETR:EUZ)?
Eckert & Ziegler SE ( ETR:EUZ ), is not the largest company out there, but it led the XTRA gainers with a relatively...Analysis Article • Apr 27
Eckert & Ziegler SE (ETR:EUZ) Investors Are Less Pessimistic Than Expected
With a price-to-earnings (or "P/E") ratio of 25.5x Eckert & Ziegler SE ( ETR:EUZ ) may be sending very bearish signals...Analysis Article • Apr 12
Here's Why Eckert & Ziegler (ETR:EUZ) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Mar 06
Slowing Rates Of Return At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Leave Little Room For Excitement
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...Analysis Article • Jan 04
What Eckert & Ziegler Strahlen- und Medizintechnik AG's (ETR:EUZ) P/E Is Not Telling You
With a price-to-earnings (or "P/E") ratio of 29.5x Eckert & Ziegler Strahlen- und Medizintechnik AG ( ETR:EUZ ) may be...Analysis Article • Dec 20
Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Nov 15
Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Hasn't Managed To Accelerate Its Returns
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...Analysis Article • Oct 01
What Is Eckert & Ziegler Strahlen- und Medizintechnik AG's (ETR:EUZ) Share Price Doing?
Eckert & Ziegler Strahlen- und Medizintechnik AG ( ETR:EUZ ), might not be a large cap stock, but it saw a decent share...Analysis Article • Aug 22
A Look At The Intrinsic Value Of Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)
Key Insights Eckert & Ziegler Strahlen- und Medizintechnik's estimated fair value is €36.79 based on 2 Stage Free Cash...Analysis Article • Jul 16
These 4 Measures Indicate That Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Jun 22
Is It Time To Consider Buying Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Eckert & Ziegler Strahlen- und Medizintechnik AG ( ETR:EUZ ), is not the largest company out there, but it saw...Analysis Article • May 17
The Return Trends At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Look Promising
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analysis Article • Mar 20
Is Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ) Potentially Undervalued?
Eckert & Ziegler Strahlen- und Medizintechnik AG ( ETR:EUZ ), is not the largest company out there, but it received a...Analysis Article • Jan 24
Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Returns Have Hit A Wall
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Oct 27
We Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Oct 05
Is It Time To Consider Buying Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
While Eckert & Ziegler Strahlen- und Medizintechnik AG ( ETR:EUZ ) might not be the most widely known stock at the...Analysis Article • Aug 21
Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Has Some Way To Go To Become A Multi-Bagger
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Shareholder Returns
| EUZ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.2% | -3.9% | -1.5% |
| 1Y | -29.3% | -28.9% | 0.2% |
Return vs Industry: EUZ underperformed the German Medical Equipment industry which returned -27.6% over the past year.
Return vs Market: EUZ underperformed the German Market which returned 1.9% over the past year.
Price Volatility
| EUZ volatility | |
|---|---|
| EUZ Average Weekly Movement | 5.4% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: EUZ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: EUZ's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,100 | Harald Hasselmann | www.ezag.com |
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services.
Eckert & Ziegler SE Fundamentals Summary
| EUZ fundamental statistics | |
|---|---|
| Market cap | €976.82m |
| Earnings (TTM) | €49.44m |
| Revenue (TTM) | €316.71m |
19.5x
P/E Ratio3.0x
P/S RatioIs EUZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EUZ income statement (TTM) | |
|---|---|
| Revenue | €316.71m |
| Cost of Revenue | €161.80m |
| Gross Profit | €154.91m |
| Other Expenses | €105.47m |
| Earnings | €49.44m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 13, 2026
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 48.91% |
| Net Profit Margin | 15.61% |
| Debt/Equity Ratio | 4.4% |
How did EUZ perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield28%
Payout RatioDoes EUZ pay a reliable dividends?
See EUZ dividend history and benchmarks| Eckert & Ziegler dividend dates | |
|---|---|
| Ex Dividend Date | Jun 25 2026 |
| Dividend Pay Date | Jun 29 2026 |
| Days until Ex dividend | 20 days |
| Days until Dividend pay date | 24 days |
Does EUZ pay a reliable dividends?
See EUZ dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/03 13:25 |
| End of Day Share Price | 2026/06/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eckert & Ziegler SE is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Thielmann | Berenberg |
| Christian Ehmann | Berenberg |
| Adrian Kowollik | Dr. Kalliwoda Research |